ISRCTN17222211已完成未知
Adjuvant Tamoxifen Treatment - offer more? To assess reliably the balance of benefits and risks of prolonging adjuvant tamoxifen treatment by 5 years for women with breast cancer
The University of Birmingham (UK)0 个研究点目标入组 6,953 人开始时间: 2001年3月22日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 6,953
研究概览
简要总结
2019 results in https://pubmed.ncbi.nlm.nih.gov/31504126/ (added 23/10/2020)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Any woman who has had complete excision of breast carcinoma
- •2. Any primary treatment
- •3. At least 2 years of prior adjuvant tamoxifen treatment (5 recommended)
- •4. Clinically relapse free
- •5. No definite indications or contraindications for further tamoxifen treatment: uncertainty as to whether further tamoxifen treatment will be of benefit
- •6. Where possible, ER status should be known prior to randomisation
排除标准
- •Not provided at time of registration
研究者
相似试验
已完成
不适用
Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 PolymorphismsBreast CancerCYP2D6 PolymorphismNCT01075802Western Sydney Local Health District121
已完成
3 期
Phase III Randomized Adjuvant Study of Tamoxifen Alone Versus Sequential Tamoxifen and Anastrozole in Hormone-Responsive Postmenopausal Breast Cancer PatientsHormone-responsive postmenopausal primary breast cancerJPRN-C000000056-SAS BC 03 executive committee2,500
已完成
3 期
Adjuvant tamoxifen - longer against shorterEarly Breast CancerACTRN12606000533594Breast Cancer Trials20,000
已完成
2 期
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the BreastDuctal Breast Carcinoma In SituEstrogen Receptor PositiveNCT02993159Northwestern University100
已完成
4 期
Pharmacology of Adjuvant Hormonotherapy in Breast CancerHormono-depending Adjuvant Breast CancerNCT01127295Institut Claudius Regaud2,000